Connect with us

Investing

AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio

Published

on

© Reuters. FILE PHOTO: A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo

(Reuters) – AbbVie (NYSE:) said on Thursday it will buy drugmaker ImmunoGen (NASDAQ:) for $10.1 billion, boosting its presence in the market for cancer treatments.

The drugmaker will pay $31.26 per ImmunoGen share in cash, representing a premium of 94.6% to the last closing price.

This transaction is expected to close in the middle of 2024, AbbVie said.

Read the full article here

Trending